Compare ASTH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | RZLT |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.7M |
| IPO Year | N/A | N/A |
| Metric | ASTH | RZLT |
|---|---|---|
| Price | $22.07 | $10.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $43.00 | $15.33 |
| AVG Volume (30 Days) | 590.6K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,896,452,000.00 | N/A |
| Revenue This Year | $58.37 | N/A |
| Revenue Next Year | $25.48 | N/A |
| P/E Ratio | $116.65 | ★ N/A |
| Revenue Growth | ★ 68.17 | N/A |
| 52 Week Low | $20.12 | $2.22 |
| 52 Week High | $43.70 | $11.46 |
| Indicator | ASTH | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 61.40 |
| Support Level | $22.62 | $8.84 |
| Resistance Level | $23.67 | $9.82 |
| Average True Range (ATR) | 1.13 | 0.64 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 53.95 | 83.58 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.